Spyre Therapeutics (SYRE) Assets Average (2016 - 2026)
Spyre Therapeutics posted quarterly Assets Average of $770.9 million for Q1 2026, up 30.85% year-on-year from $589.1 million in Q1 2025, and up 20.22% on a QoQ basis from $641.2 million in Q4 2025.
Spyre Therapeutics (SYRE) has 11 years of Assets Average data on file, last reported at $770.9 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average rose 30.85% year-over-year to $770.9 million; the trailing twelve-month figure through Mar 2026 stood at $770.9 million (up 30.85% YoY), and the FY2025 full-year result was $693.1 million, up 45.87% from the prior year.
- Assets Average for Q1 2026 stood at $770.9 million, up from $641.2 million in the prior quarter.
- Across five years, Assets Average topped out at $770.9 million in Q1 2026 and bottomed at $61.8 million in Q1 2023.
- The 5-year median for Assets Average is $414.7 million (2024), against an average of $351.7 million.
- The widest annual swing landed in 2022, when Assets Average plunged 40.63%; it then soared 571.1% in 2024.
- A 5-year view of Assets Average shows it stood at $81.4 million in 2022, then surged by 237.49% to $274.6 million in 2023, then soared by 87.49% to $514.8 million in 2024, then gained by 24.56% to $641.2 million in 2025, then grew by 20.22% to $770.9 million in 2026.
- The last three Assets Average figures came in at $770.9 million (Q1 2026), $641.2 million (Q4 2025), and $521.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | 770.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 770.87 Mn |
| Dec 31, 2025 | 641.19 Mn |
| Sep 30, 2025 | 521.72 Mn |
| Jun 30, 2025 | 554.31 Mn |
| Mar 31, 2025 | 589.13 Mn |
| Dec 31, 2024 | 514.79 Mn |
| Sep 30, 2024 | 428.58 Mn |
| Jun 30, 2024 | 461.83 Mn |
| Mar 31, 2024 | 414.73 Mn |
| Dec 31, 2023 | 274.56 Mn |
| Sep 30, 2023 | 225.40 Mn |
| Jun 30, 2023 | 147.99 Mn |
| Mar 31, 2023 | 61.80 Mn |
| Dec 31, 2022 | 81.36 Mn |
| Sep 30, 2022 | 99.14 Mn |
| Jun 30, 2022 | 94.94 Mn |
| Mar 31, 2022 | 96.55 Mn |
| Dec 31, 2021 | 119.49 Mn |
| Sep 30, 2021 | 138.02 Mn |
| Jun 30, 2021 | 155.30 Mn |
| Mar 31, 2021 | 162.62 Mn |
| Dec 31, 2020 | 158.62 Mn |
| Sep 30, 2020 | 164.27 Mn |
| Jun 30, 2020 | 118.85 Mn |
| Mar 31, 2020 | 73.98 Mn |
| Dec 31, 2019 | 91.64 Mn |
| Sep 30, 2019 | 108.80 Mn |
| Jun 30, 2019 | 123.01 Mn |
| Mar 31, 2019 | 103.13 Mn |
| Dec 31, 2018 | 74.51 Mn |
| Sep 30, 2018 | 75.50 Mn |
| Jun 30, 2018 | 64.75 Mn |
| Mar 31, 2018 | 52.93 Mn |
| Dec 31, 2017 | 58.29 Mn |
| Sep 30, 2017 | 63.82 Mn |
| Jun 30, 2017 | 64.21 Mn |
| Mar 31, 2017 | 64.17 Mn |
| Dec 31, 2016 | 69.56 Mn |
| Sep 30, 2016 | 74.68 Mn |
| Jun 30, 2016 | 56.42 Mn |
| Mar 31, 2016 | 37.10 Mn |